<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2019-23-4-73-79</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1724</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Белок S100B, нейронспецифичная енолаза и когнитивная дисфункция у пациентов с хронической болезнью почек</article-title><trans-title-group xml:lang="en"><trans-title>S100B protein, neuron specific enolase and cognitive dysfunction in patients with chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2139-5446</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомина Наталья Викторовна - докор медицинских наук, профессор, кафедра факультетской терапии, профессиональных болезней и эндокринологии.</p><p>650029, Кемерово, ул. Ворошилова, д. 22, Тел.: 8 905-960-63-36</p></bio><bio xml:lang="en"><p>Natalia V. Fomina - MD, PhD, DMedSci., Prof., Department of faculty therapy chair, professional disease and endocrinology</p><p>650029, Kemerovo, Voroshilova street, 22a, Phone (384) 2396459</p></bio><email xlink:type="simple">natafomin11@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Егорова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Egorova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Егорова Марина Викторовна - нефролог.</p><p>650029, Кемерово, ул. Ворошилова, д. 22, Тел.: 8 923-611-30-85</p></bio><bio xml:lang="en"><p>Marina V. Egorova – MD, nephrologist.</p><p>650066, Kemerovo, Oktyabrskyprospect, 22, Phone 8 923-611-30-85</p></bio><email xlink:type="simple">marina-egorova-85@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смакотина</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Smakotina</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смакотина Светлана Анатольевна - докор медицинских наук, профессор, кафедра факультетской терапии, профессиональных болезней и эндокринологии.</p><p>650029, Кемерово, ул. Ворошилова, д. 22, Тел.: 8 903-993-00-41</p></bio><bio xml:lang="en"><p>Svetlana A. Smakotina - MD, PhD, DMedSci., Prof., Department of faculty therapy chair, professional disease and endocrinology</p><p>650029, Kemerovo, Voroshilova street, 22a, Phone 8 903-993-00-41</p></bio><email xlink:type="simple">smak67@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Квиткова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kvitkova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Квиткова Людмила Владимировна - докор медицинских наук, профессор, кафедра факультетской терапии, профессиональных болезней и эндокринологии.</p><p>650029, Кемерово, ул. Ворошилова, д. 22, Тел.: 8 951-188-99-68</p></bio><bio xml:lang="en"><p>Luydmila Vl. Kvitkova - MD, PhD, DMedSci., Prof., Department of faculty therapy chair, professional disease and endocrinology.</p><p>650029, Kemerovo, Voroshilova street, 22a, Phone 8 951188-99-68</p></bio><email xlink:type="simple">kvitkova_lv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кемеровский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kemerovo State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2019</year></pub-date><volume>23</volume><issue>4</issue><fpage>73</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фомина Н.В., Егорова М.В., Смакотина С.А., Квиткова Л.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Фомина Н.В., Егорова М.В., Смакотина С.А., Квиткова Л.В.</copyright-holder><copyright-holder xml:lang="en">Fomina N.V., Egorova M.V., Smakotina S.A., Kvitkova L.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1724">https://journal.nephrolog.ru/jour/article/view/1724</self-uri><abstract><p>Цель исследования - оценка взаимосвязи когнитивных функций и биохимических показателей крови белка S100B, нейронспецифичной енолазы у пациентов молодого и среднего возраста с ХБП 1-3 стадии.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Обследовано 108 пациентов молодого и среднего возраста с 1-3 стадией хронической болезнью почек (ХБП). В исследование было включено 70 (64,8%) пациентов с 1 стадией ХБП, 18 (16,6%) пациентов ХБП 2 и 20 (18,5%) пациентов с 3 (а+б) стадией ХБП. Когнитивные нарушения оценивались с помощью опросника MMSE, программного комплекса Status PF.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с ХБП 2-3 стадии в сравнении с пациентами с 1 стадией ХБП когнитивные функции были нарушены в большей степени. В этих группах сравнения выявлены статистически значимые различия средней экспозиции простой зрительной моторной реакции (ПЗМР), (р=0,008); минимальной и средней экспозиции сложной зрительномоторной реакции (р=0,004; р=0,0001). Отрицательная статистически значимая корреляционная связь выявлена между величиной белка S100B и скоростью клубочковой фильтрации СКФ (Rs=-0,37; p=0,001). Обнаружены положительные корреляционные взаимосвязи между минимальной экспозицией сложной зрительно-моторной реакцией (СЗМР) и уровнем цистатина С; между средней экспозицией СЗМР и уровнем цистатина С (Rs=0,50, p=0,001; Rs=0,37, p=0,01), а также отрицательная связь между количеством ошибок при выполнении СЗМР и уровнем цистатина С (Rs=-0,33, p=0,02). Определена положительная корреляционная связь между белком S100B и минимальной, средней экспозицией СЗМР (Rs=0,29, p=0,001; Rs=0,39, p=0,001). Слабая положительная корреляционная связь выявлена между величиной белка S100B и количеством запаздываний при оценке реакции на движущийся объект (Rs=0,23; p=0,04). Установлены статистически значимые отрицательные связи между белком S100B и суммарным временем опережения, количеством точных движений в тестах, оценивающих реакцию на движущийся объект (Rs=-0,39, p=0,001; Rs=-0,31, p=0,001). Корреляционных связей между нейроспецифичной енолазой и показателями нейродинамики выявлено не было.</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с ХБП 1-3 стадий выявляются легкие когнитивные нарушения, которые ассоциируются со скоростью клубочковой фильтрации, уровнем цистатина С крови, белка S100B.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The aim</title><p>The aim: to identify the correlations between cognitive dysfunctions and biochemical factors of blood - S100B protein and neuron-specific enolase - in young and middle-aged patients with chronic kidney disease (CKD) Stages 1-3.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. 108 young and middle-aged patients with chronic kidney disease Stages 1-3 were examined. 70 patients (64.8%) were diagnosed with chronic kidney disease Stage 1, 18 patients (16.6%) had CKD Stage 2, and 20 patients (18.5%) had CKD Stage 3 (A+B). Cognitive dysfunctions were assessed with MMSE survey and software package Status PF.</p></sec><sec><title>Results</title><p>Results. The patients with CKD Stages 2-3 showed a higher degree of cognitive dysfunctions than those with CKD Stage 1. Statistically significant differences in the average exposure in simple visual-motor response (p=0.008) and minimal and average exposures in complex visual-motor response (р=0,004; р=0,0001) between these two groups of patients were discovered. A statistically significant negative correlation between the level of S100B protein and the glomerular filtration rate was found (Rs=-0,37; p=0,001). Positive correlations were discovered between the minimal exposure in complex visual-motor response and the level of cystatin C, and the average exposure in complex visual-motor response and the level of cystatin C (Rs=0,50, p=0,001; Rs=0,37, p=0,01), while negative correlations were found between the number of errors in complex visual-motor response and the level of cystatin C (Rs=-0,33, p=0,02). Positive correlation was discovered between the level of S100B protein and the minimal and average exposures in complex visual-motor response (Rs=0,29, p=0,001; Rs=0,39, p=0,001). A weak positive correlation was found between the level of S100B protein and the number of delays in reactions to the moving object (Rs=0,23; p=0,04). Statistically significant negative correlations were discovered between S100B protein and the total anticipation time and the number of accurate reactions in tests with moving objects (Rs=-0,39, p=0,001; Rs=-0,31, p=0,001). No correlations between neuron-specific enolase and neurodynamic indicators were discovered.</p></sec><sec><title>Conclusion</title><p>Conclusion. Patients with chronic kidney disease (CKD) Stages 1-3 demonstrated minor cognitive dysfunctions associated with the glomerular filtration rate, cystatin C level, and S100B protein level.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>когнитивные нарушения</kwd><kwd>хроническая болезнь почек</kwd><kwd>нейронспецифичная енолаза</kwd><kwd>белкок S100B</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cognitive dysfunctions</kwd><kwd>chronic kidney disease</kwd><kwd>neuron-specific enolase</kwd><kwd>S100B protein</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kurella M, Mapes DL, Port FK, Chertow GM. Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2006; 21(9): 2543-2548. Doi: 10.1093/ndt/gfl275</mixed-citation><mixed-citation xml:lang="en">Kurella M, Mapes DL, Port FK, Chertow GM. Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2006; 21(9): 2543-2548. Doi: 10.1093/ndt/gfl275</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Helmer C, Stengel B, Metzger M et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011; 77(23): 2043-2051. Doi:10.1212/WNL.0b013-e31823b476558</mixed-citation><mixed-citation xml:lang="en">Helmer C, Stengel B, Metzger M et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011; 77(23): 2043-2051. Doi:10.1212/WNL.0b013-e31823b476558</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yokobori S, Hosein K, Burks S et al. Biomarkers for the clinical differential diagnosis in traumatic brain injury: a systematic review. CNS Neurosci Ther 2013;19(8): 556-565. Doi: 10.1111/cns.12127</mixed-citation><mixed-citation xml:lang="en">Yokobori S, Hosein K, Burks S et al. Biomarkers for the clinical differential diagnosis in traumatic brain injury: a systematic review. CNS Neurosci Ther 2013;19(8): 556-565. Doi: 10.1111/cns.12127</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mercier E, Tardif PA, Cameron PA et al. Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review. Brain Inj 2018; 32(1): 29-40. Doi: 10.1080/02699052.2017.1385097</mixed-citation><mixed-citation xml:lang="en">Mercier E, Tardif PA, Cameron PA et al. Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review. Brain Inj 2018; 32(1): 29-40. Doi: 10.1080/02699052.2017.1385097</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Quevedo A, Garcia SG, Concepcion OF et al. Increased serum S-100B and neuron specific enolase - Potential markers of early nervous system involvement in essential hypertension. Clin Biochem 2011; 44(2-3): 154-159. Doi: 10.1016/j.clinbiochem.-2010.11.006</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Quevedo A, Garcia SG, Concepcion OF et al. Increased serum S-100B and neuron specific enolase - Potential markers of early nervous system involvement in essential hypertension. Clin Biochem 2011; 44(2-3): 154-159. Doi: 10.1016/j.clinbiochem.-2010.11.006</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции: национальные рекомендации. Клин нефрология 2014; (2): 4-29</mixed-citation><mixed-citation xml:lang="en">Serdechno-sosudisty'j risk i hronicheskaya bolezn' pochek: strategii kar-dionefroprotekcii : nacional'ny'e rekomendacii. Klin nefrologiya 2014; (2): 4-29</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Яхно НН. Когнитивные расстройства в неврологической клинике. Невролжурн 2006; 11 (прил. № 1): 4-12</mixed-citation><mixed-citation xml:lang="en">Yahno NN. Kognitivny'e rasstrojstva v nevrologicheskoj klinike. Nevrol zhurn 2006; 11 (pril. № 1): 4-12</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Etgen T, Chonchol M, Forstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 2012; 35(5): 474-482. Doi: 10.1159/000338135</mixed-citation><mixed-citation xml:lang="en">Etgen T, Chonchol M, Forstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 2012; 35(5): 474-482. Doi: 10.1159/000338135</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Berger I, Wu S, Masson P et al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med 2016; 14(1): 206. Doi: 10.1186/s12916-016-0745-9</mixed-citation><mixed-citation xml:lang="en">Berger I, Wu S, Masson P et al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med 2016; 14(1): 206. Doi: 10.1186/s12916-016-0745-9</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Seliger SL, Siscovick DS, Stehman-Breen CO et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. JASN 2004; 15 (7): 1904-1911. Doi.org/10.1097/01.ASN.-0000131529.60019.FA</mixed-citation><mixed-citation xml:lang="en">Seliger SL, Siscovick DS, Stehman-Breen CO et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. JASN 2004; 15 (7): 1904-1911. Doi.org/10.1097/01.ASN.-0000131529.60019.FA</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Da Matta SM, Janaina Matos M, Kummer AM et al. Cognitive alterations in chronic kidney disease: an update. J Bras Nefrol 2014; 36 (2): 241-245. dx.Doi.org/10.5935/0101-2800.2014003</mixed-citation><mixed-citation xml:lang="en">Da Matta SM, Janaina Matos M, Kummer AM et al. Cognitive alterations in chronic kidney disease: an update. J Bras Nefrol 2014; 36 (2): 241-245. dx.Doi.org/10.5935/0101-2800.2014003</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Martens RJ, Kooman JP, Stehouwer CD et al. Estimated GFR, albuminuria, and cognitive performance: The Maastricht Study. Am J Kidney Dis 2017; 69 (2): 179-191. Doi: 10.1053/j.ajkd.2016.04.017</mixed-citation><mixed-citation xml:lang="en">Martens RJ, Kooman JP, Stehouwer CD et al. Estimated GFR, albuminuria, and cognitive performance: The Maastricht Study. Am J Kidney Dis 2017; 69 (2): 179-191. Doi: 10.1053/j.ajkd.2016.04.017</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Murray AM. The brain and the kidney connection: a model of accelerated vascular cognitive impairment. Neurology 2009; 73 (12): 916-917. Doi: 10.1212/WNL.0b013e3181b99a2e</mixed-citation><mixed-citation xml:lang="en">Murray AM. The brain and the kidney connection: a model of accelerated vascular cognitive impairment. Neurology 2009; 73 (12): 916-917. Doi: 10.1212/WNL.0b013e3181b99a2e</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Григорьев ЕВ, Вавин ГВ, Гришанова ТГ и др. Нейронспецифические белки - маркеры энцефалопатии при тяжелой сочетанной травме. Медицина неотлож состояний 2010; (2): 72-76</mixed-citation><mixed-citation xml:lang="en">Grigor'ev EV, Vavin GV, Grishanova TG i dr. Nejronspecificheskie belki - markery' e'ncefalopatii pri tyazheloj sochetannoj travme. Medicina neotlozh. sostoyanij 2010; (2): 72-76</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cases A, Filella X,Molina R et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57(2):183-186. Doi: 10.1159/000186247</mixed-citation><mixed-citation xml:lang="en">Cases A, Filella X,Molina R et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57(2):183-186. Doi: 10.1159/000186247</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Petzold A, Green AJ, Keir G et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care ed 2002; 30(12): 2705-2710. Doi: 10.1097/01.CCM.0000034992.41554.D9</mixed-citation><mixed-citation xml:lang="en">Petzold A, Green AJ, Keir G et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care ed 2002; 30(12): 2705-2710. Doi: 10.1097/01.CCM.0000034992.41554.D9</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang F, Zou ZR, Yuan D et al. Correlation between serum S100p protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case-control study. Biosci Rep 2017; 37(2). Doi: 10.1042/BSR20160446</mixed-citation><mixed-citation xml:lang="en">Wang F, Zou ZR, Yuan D et al. Correlation between serum S100p protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case-control study. Biosci Rep 2017; 37(2). Doi: 10.1042/BSR20160446</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
